Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Back to The Tape

Zacks Investment Research

20 Jul 2026, 13:55 UTC · 14h ago

Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

ShareX LinkedIn

Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?

What the story claims

4 claims · each scored for market impact

What matters in this story

1
Johnson & Johnson raised its full-year 2026 sales and earnings guidance following a strong second quarter. — Upward revisions to annual guidance typically signal confidence in future cash flows and act as a positive catalyst for the stock price.
+0.60
2
J&J's second-quarter 2026 earnings rose 4.7% and sales rose 6.6% year-over-year, beating analyst estimates. — Earnings beats provide immediate positive momentum, though the magnitude of the growth is moderate.
+0.40
3
The Innovative Medicine segment continues to grow despite the loss of exclusivity for the blockbuster drug Stelara. — The ability to offset the loss of a major patent through other drugs reduces the perceived risk of a revenue cliff.
+0.30
4

6 related stories

GlobeNewsWire
4h ago
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
- earnings
- guidance
- healthcare
Read

Should You Buy, Sell or Ho… — JNJ +0.80 | NewsImpactScreener

Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?

What matters in this story

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?

What matters in this story

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know

A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound

Here's Why Pacific Biosciences of California (PACB) Fell More Than Broader Market

BlackBerry Is Ripe For Accumulation Amid A Comeback

GRAL DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages GRAIL, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 4 Deadline in Securities Class Action – GRAL

Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?

What matters in this story

Next reads from the same story arc

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

Should You Buy, Sell or Hold J&J's Stock Post a Robust Q2 Performance?

What matters in this story

Next reads from the same story arc

Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress

How each ticker is affected

Track these names every morning.

Impact by category

Biggest drivers

Most positively impacted

Most negatively impacted

Corcept's CFO Set His Selling Plan the Month the Stock Fell 50% — Here's What Investors Should Know

A Corcept Director Holds 1.5 Million Shares Through a 50% Crash and Rebound

Here's Why Pacific Biosciences of California (PACB) Fell More Than Broader Market

BlackBerry Is Ripe For Accumulation Amid A Comeback

GRAL DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages GRAIL, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 4 Deadline in Securities Class Action – GRAL